secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioAtla, Inc. (BCAB)
CIK:        0001826892
Form:       8-K
Filed at:   2022-11-03T23:59:59+00:00
Accession:  0000950170-22-021833
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioAtla reports Q3 net loss $25.8M; cash $178.1M; BA3011 NSCLC shows 50% ORR in monotherapy
--------------------------------------------------------------------------------

- Cash and cash equivalents $178.1M as of Sep 30, 2022, expected to fund operations into 2H24.
- Net loss $25.8M for Q3 2022 vs $22.9M in Q3 2021; R&D expense increased to $19.8M.
- BA3011 Phase 2 NSCLC: 4 PRs in monotherapy (ORR 50%) in non-squamous group; 1 CR in combination.
- BA3011 UPS part 2 enrollment anticipated to start by year-end after FDA feedback; potential registrational path.
- BA3071 Phase 1: first two cohorts completed without DLTs or SAEs; BA3182 IND on track by year-end.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826892/000095017022021833/0000950170-22-021833-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826892/000095017022021833/bcab-20221103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-021833

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer